77232-26-9

Upstream product

• 14062-19-2 p-tolylacetic acid ethyl ester 
• 143-37-3 acetamidine 
• 27835-00-3 ethyl (4-methylbenzoyl)acetate 
• 124-42-5 acetamidine hydrochloride 
• 122-00-9 para-methylacetophenone 

Downstream Products

• 77232-27-0 2-methyl-4-chloro-6-(4-methylphenyl)-pyrimidine 
• 77232-28-1 2-Methyl-4-p-tolyl-pyrimidine 
• 1579270-46-4 2-methyl-6-(p-tolyl)-5-(trifluoromethyl)pyrimidin-4(3H)-one 
• 1055923-53-9 5-(6-chloro-2-methylpyrimidin-4-yl)-2-methylbenzene sulphonamide 
• 1055923-54-0 5-(6-hydrazino-2-methylpyrimidin-4-yl)-2-methyl benzenesulphonamide 
• 1055923-52-8 2-methyl-5-{2-methyl-6-[(3-methyl-2,5-dioxo-2,5-dihydro-1H-pyrrol-1yl)amino]pyrimidin-4-yl}benzenesulphonamide 

Relevant academic research and scientific papers

Manganese(III)-mediated direct Csp2-H radical trifluoromethylation of coumarins with sodium trifluoromethanesulfinate

Mn(OAc)3-mediated direct Csp2-H radical trifluoromethylation of coumarins with CF3SO2Na (Langlois reagent) to afford selective 3-trifluoromethyl coumarins in moderate to good yields is described. This methodology can also be applied to the trifluoromethylation of quinolinones and pyrimidinones. The Royal Society of Chemistry 2014.

New heterocyclic compounds

Provided herein are heterocyclic compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof, wherein R1, R2, R3, R4 and R5 are as described herein. Further described herein in particular are heterocyclic compounds of the formula (I) for treating various diseases. and disorders by administering in a patient one or more TNF-α, Thromboxane synthase, 5-LOX, and PDE4 inhibitors. In particular described herein are methods for treating immunological diseases, inflammation, pain disorder, rheumatoid arthritis; osteoporosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; ischemic heart disease; atherosclerosis; cancer; ischemic-induced cell damage; pancreatic beta cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; muscle degeneration; cachexia; asthma; bone resorption diseases; ischemia reperfusion injury; brain trauma; multiple sclerosis; sepsis; septic shock; toxic shock syndrome; fever, and myalgias due to infection and diseases mediated by HIV-1; HIV-2; HIV-3; cytomegalovirus (CMV); influenza; adenovirus; the herpes viruses (including HSV-1, HSV-2) and herpes zoster viruses in a mammal comprising administering an effective amount of a compound of formula (I).

Ueber die Herstellung von Styryl- und Stylbenyl-Derivaten des Pyrimidins

2- and 4-(p-Tolyl)-substituted pyrimidines react with anils of hetero-aromatic aldehydes in the presence of dimethylformamide and potassium hydroxide or potassium t-butoxide to yield the corresponding 2- and 4-pyrimidines or